Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Derya Kabacaoğlu"'
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Pancreatic ductal adenocarcinoma (PDAC), as the most frequent form of pancreatic malignancy, still is associated with a dismal prognosis. Due to its late detection, most patients are ineligible for surgery, and chemotherapeutic options are limited. T
Externí odkaz:
https://doaj.org/article/bad7f7a9c6d54f36a32fbc9d8cf63ce3
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 6, Iss 1, Pp 1-2 (2021)
Externí odkaz:
https://doaj.org/article/3c681973671a460696ed2289e2b2925e
Autor:
Katrin J. Ciecielski, Antonio Mulero-Sánchez, Alexandra Berninger, Laura Ruiz Cañas, Astrid Bosma, Kıvanç Görgülü, Nan Wu, Kalliope N. Diakopoulos, Ezgi Kaya-Aksoy, Dietrich A. Ruess, Derya Kabacaoğlu, Fränze Schmidt, Larissa Heinemann, Yuhui Fan, Bram Thijssen, Marieke van de Ven, Natalie Proost, Susanne Kossatz, Wolfgang A. Weber, Bruno Sainz, Rene Bernards, Hana Algül, Marina Lesina, Sara Mainardi
Mutant KRAS is present in over 90% of pancreatic as well as 30-40% of lung and colorectal cancers and is one of the most common oncogenic drivers. Despite decades of research and the recent emergence of isoform-specific KRASG12C-inhibitors, most muta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::820e350037b052f68e3efa83c6a905fd
https://doi.org/10.1101/2021.12.14.472574
https://doi.org/10.1101/2021.12.14.472574
Autor:
Katrin J. Frank, Antonio Mulero-Sánchez, Alexandra Berninger, Laura Ruiz-Cañas, Astrid Bosma, Kıvanç Görgülü, Nan Wu, Kalliope N. Diakopoulos, Ezgi Kaya-Aksoy, Dietrich A. Ruess, Derya Kabacaoğlu, Fränze Schmidt, Larissa Kohlmann, Olaf van Tellingen, Bram Thijssen, Marieke van de Ven, Natalie Proost, Susanne Kossatz, Wolfgang A. Weber, Bruno Sainz, Rene Bernards, Hana Algül, Marina Lesina, Sara Mainardi
Publikováno v:
Cell Reports Medicine. 3:100815
Over 90% of pancreatic cancers present mutations in KRAS, one of the most common oncogenic drivers overall. Currently, most KRAS mutant isoforms cannot be targeted directly. Moreover, targeting single RAS downstream effectors induces adaptive resista
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46e7415e46cb288c9db1eda723748e3b
https://doi.org/10.1016/j.xcrm.2022.100815
https://doi.org/10.1016/j.xcrm.2022.100815
Autor:
Marta Alonso-Nocelo, Laura Ruiz-Cañas, Patricia Sancho, Kıvanç Görgülü, Sonia Alcalá, Coral Pedrero, Mireia Vallespinos, Juan Carlos López-Gil, Marina Ochando, Elena García-García, Sara Maria David Trabulo, Paola Martinelli, Patricia Sánchez-Tomero, Carmen Sánchez-Palomo, Patricia Gonzalez-Santamaría, Lourdes Yuste, Sonja Maria Wörmann, Derya Kabacaoğlu, Julie Earl, Alberto Martin, Fernando Salvador, Sandra Valle, Laura Martin-Hijano, Alfredo Carrato, Mert Erkan, Laura García-Bermejo, Patrick C Hermann, Hana Algül, Gema Moreno-Bueno, Christopher Heeschen, Francisco Portillo, Amparo Cano, Bruno Sainz
Publikováno v:
Gut.
[Objective]: The lysyl oxidase-like protein 2 (LOXL2) contributes to tumour progression and metastasis in different tumour entities, but its role in pancreatic ductal adenocarcinoma (PDAC) has not been evaluated in immunocompetent in vivo PDAC models
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05d20adf78551aa658e5d8fb4171bdb9
https://pubmed.ncbi.nlm.nih.gov/35428659
https://pubmed.ncbi.nlm.nih.gov/35428659